institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

Similar Splenic, Symptom Responses Are Reported With Ruxolitinib Combos in Myelofibrosis With Anemia

Summary by cancernetwork.com
Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

cancernetwork.com broke the news in on Friday, June 13, 2025.
Sources are mostly out of (0)